Benzenealkanoic acids for cardiovascular diseases
US5618941A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 15, 1995 |
| Grant date | Apr 8, 1997 |
| Priority date | — |
| Expiry date | Mar 15, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of formula (I) wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each H or C.sub.1 -C.sub.4 alkyl; R.sup.5 is (CH.sub.2).sub.m NHSO.sub.2 R.sup.6 or (CH).sub.m NHCOR.sup.6 ; R.sup.6 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl optionally substituted by aryl, aryl or heteroaryl; R.sup.7 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, CF.sub.3, OCF.sub.3, CN, CONH.sub.2, or S(O).sub.n (C.sub.1 -C.sub.4 alkyl); X is CH.sub.2, CHCH.sub.3, CH(OH), C(OH)CH.sub.3, C.dbd.CH.sub.2, CO or O; m is 0 or 1 and n is 0, 1 or 2, and their pharmaceutically acceptable salts and biolabile esters, are antagonists of thromboxane A.sub.2 of utility, particulary in combination with a thromboxane synthetase inhibitor, in the treatment of atherosclerosis and unstable angina and for prevention of reocclusion after percutaneous transluminal angioplasty.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.